{
    "organizations": [],
    "uuid": "a453f4b7fde6a8262830a67d63056abeb1b8d3ab",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-medivir-intends-to-make-a-directed/brief-medivir-intends-to-make-a-directed-share-issue-idUSFWN1PR166",
    "ord_in_thread": 0,
    "title": "BRIEF-Medivir Intends To Make A Directed Share Issue",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 1 (Reuters) - Medivir Ab:\n* MEDIVIR INTENDS TO MAKE A DIRECTED SHARE ISSUE * MEDIVIR - ‍MEDIVIR IS IN DISCUSSIONS WITH FDA ON DESIGN OF PIVOTAL PHASE III CTCL STUDY FOR REMETINOSTAT​\n* MEDIVIR - INTENDS TO EXECUTE A DIRECTED ISSUE OF CLASS B SHARES TO SWEDISH AND INTERNATIONAL QUALIFIED INSTITUTIONAL INVESTORS Source text for Eikon: Further company coverage: (Bengaluru Newsroom)\n ",
    "published": "2018-02-02T00:38:00.000+02:00",
    "crawled": "2018-02-02T13:16:43.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "medivir",
        "ab",
        "medivir",
        "intends",
        "make",
        "directed",
        "share",
        "issue",
        "medivir",
        "discussion",
        "fda",
        "design",
        "pivotal",
        "phase",
        "iii",
        "ctcl",
        "study",
        "medivir",
        "intends",
        "execute",
        "directed",
        "issue",
        "class",
        "b",
        "share",
        "swedish",
        "international",
        "qualified",
        "institutional",
        "investor",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "bengaluru",
        "newsroom"
    ]
}